NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today
06 Fevereiro 2024 - 10:00AM
NightHawk Biosciences / Scorpius Holdings,
Inc. (NYSE American:
NHWK; SCPX), an integrated
contract development and manufacturing organization (CDMO), today
announced that it had completed its name change from NightHawk
Biosciences, Inc. to Scorpius Holdings, Inc., to better reflect the
Company’s successful shift into a pure-play, large molecule
biomanufacturing CDMO. In connection with the name change, the
Company’s ticker will change to “SCPX” effective today, February 6,
2024. The name and symbol changes do not affect the Company's share
structure or the rights of the Company's shareholders, and no
further action will be required by existing shareholders.
Jeff Wolf, CEO of Scorpius, stated, "Changing
our name to Scorpius Holdings reflects our evolution into a
revenue-generating biomanufacturing company and expansion of our
CDMO services. The biopharmaceutical sector is currently grappling
with a severe shortage of clinical-scale biologic manufacturing
capacity, a situation exacerbated by the rising demand for large
molecule CDMO services. Our cutting-edge San Antonio, Texas
facility is strategically positioned to fill this critical void.
The feedback from our key biotech and pharmaceutical customers has
been overwhelmingly positive, as reflected in our enhanced sales
pipeline. We are eager to advance these initiatives under the
Scorpius banner."
Scorpius Holdings, Inc.
Scorpius Holdings Inc. is an integrated contract
development and manufacturing organization (CDMO) focused on
rapidly advancing biologic and cell therapy programs to the clinic
and beyond. Scorpius offers a broad array of analytical testing,
process development, and manufacturing services to pharmaceutical
and biotech companies at its state-of-the-art facilities in San
Antonio, TX. With an experienced team and new, purpose-built U.S.
facilities, Scorpius is dedicated to transparent collaboration and
flexible, high-quality biologics biomanufacturing. For more
information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases, forward-looking statements can be
identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," and similar expressions, and include
statements such as the Company’s successful shift into a pure-play,
large molecule biomanufacturing CDMO; the rising demand for large
molecule CDMO services; the Company’s cutting-edge San Antonio,
Texas facility being strategically positioned to fill the critical
shortage of clinical-scale biologic manufacturing capacity in the
biopharmaceutical sector; the Company’s enhanced sales pipeline;
and advancing the Company’s initiatives under the Scorpius banner.
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
Company’s ability to expand its large molecule biomanufacturing
CDMO services and continue to grow revenue; the Company’s financing
needs, its cash balance being sufficient to sustain operations and
its ability to raise capital when needed, the Company’s ability to
leverage fixed costs and achieve long-term profitability; the
Company’s ability to obtain regulatory approvals or to comply with
ongoing regulatory requirements, regulatory limitations relating to
the Company’s ability to successfully promote its services and
compete as a pure- play CDMO, and other factors described in the
Company’s annual report on Form 10-K for the year ended December
31, 2022, subsequent quarterly reports on Form 10-Qs and any other
filings the Company makes with the SEC. The information in this
presentation is provided only as of the date presented, and the
Company undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017ir@scorpiusbiologics.com
Scorpius (AMEX:SCPX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Scorpius (AMEX:SCPX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024